A Brief Heading
Company Introduction
IMO is a medical technology company founded by researchers from Shanghai Jiao Tong University. Founded in November 2023, the company has already built a comprehensive, graphical, and one-click platform for computational screening targeting artificial intelligence protein drug design. It has collaborated with multiple listed pharmaceutical companies both domestically and internationally to accelerate protein drug development and develop its own protein drug pipelines. Additionally, it has partnered with several top-tier hospitals to develop AI-based diagnostic and predictive tools.
Mission
The mission of IMO is to use generative artificial intelligence technology to develop innovative drug screening algorithms, and is committed to solving the problems of long protein drug screening time and low success rate. Our goal is to develop efficient and accurate protein drug screening software, focusing on peptide drug screening, and conducting experimental verification of protein solubility, affinity, and activity, in order to solve major disease problems such as endocrine, digestive tract, and bone lesions. We believe that through the power of artificial intelligence, we can open a new chapter in the research and development of drugs and diagnosis and treatment, bringing greater hope and possibility to the health of all mankind.
Market Prospect
IMO is committed to accelerating research in protein drug design and focusing on developing independent peptide pipelines. The global peptide drug market was approximately USD 15.2 billion in 2010, reaching USD 28.5 billion in 2018, with a compound annual growth rate of 8.17%. Compared to the global pharmaceutical market size of approximately USD 1.3 trillion in 2018, the market share of peptide drugs accounted for only 2.19%, and the growth rate of the peptide drug market was approximately twice the overall growth rate of the global drug market.。
It is estimated that the future peptide drug market will continue to grow at a compound annual growth rate of 7.9%, reaching a market size of USD 35.8 billion in 2021 and USD 49.5 billion in 2027, indicating significant growth potential. In China, the peptide drug market size has increased from USD 6.3 billion in 2016 to USD 8.5 billion in 2020, with an annual compound growth rate of 8%. Our company’s high-throughput, full-process protein screening technology that combines wet and dry methods will lead the rapid development of the peptide drug market.
Company Technical Founders
Yu Zhangsheng
- Tenured Professor and PhD Advisor, Shanghai Jiao Tong University
- Visiting Professor, Department of Biostatistics, Yale School of Public Health
- Shanghai Outstanding Academic Leader
- Shanghai Distinguished Overseas High-Level Talent Expert
- Member of the Youth Committee, All-China Federation of Returned Overseas Chinese
- Vice Chairman of the Overseas Chinese Federation, Shanghai Jiao Tong University
- Vice President of the Clinical Statistics Specialty Committee, World Federation of Chinese Medicine Societies
- Published over 100 papers in JAMA, Journal of Hematology and Oncology (IF 23), Nature Communications, Biometrika, and others
- Deputy Editor of Statistics in Medicine, Statistical Editor for Heart Rhythm
- Editorial Board Member of Journal of Digestive Diseases and Pediatric Pulmonology
Chen Haifeng
- Professor and PhD Advisor, Shanghai Jiao Tong University
- Pujiang Talent of Shanghai
- Recipient of the First Prize for Scientific and Technological Progress in Shanghai
- Published over 130 SCI papers in international journals such as JACS, PNAS, Bioinformatics, JCTC, and JCIM
- Deputy Editor of Frontiers in Molecular Biosciences and Chemical Biology & Drug Design
- Editorial Board Member of Journal of Chemical Information and Modeling and International Journal of Molecular Sciences